↓ Skip to main content

Dove Medical Press

Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results

Overview of attention for article published in Drug Design, Development and Therapy, February 2014
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
1 X user
reddit
1 Redditor

Citations

dimensions_citation
15 Dimensions

Readers on

mendeley
48 Mendeley
Title
Combining rimonabant and fentanyl in a single entity: preparation and pharmacological results
Published in
Drug Design, Development and Therapy, February 2014
DOI 10.2147/dddt.s55045
Pubmed ID
Authors

Cristina Fernández-Fernández, Luis F Callado, Rocío Girón, Eva Sánchez, Amaia M Erdozain, José Antonio López-Moreno, Paula Morales, Fernando Rodríguez de Fonseca, Javier Fernández-Ruiz, Pilar Goya, J Javier Meana, M Isabel Martín, Nadine Jagerovic

Abstract

Based on numerous pharmacological studies that have revealed an interaction between cannabinoid and opioid systems at the molecular, neurochemical, and behavioral levels, a new series of hybrid molecules has been prepared by coupling the molecular features of two wellknown drugs, ie, rimonabant and fentanyl. The new compounds have been tested for their affinity and functionality regarding CB1 and CB2 cannabinoid and μ opioid receptors. In [(35)S]-GTPγS (guanosine 5'-O-[gamma-thio]triphosphate) binding assays from the post-mortem human frontal cortex, they proved to be CB1 cannabinoid antagonists and μ opioid antagonists. Interestingly, in vivo, the new compounds exhibited a significant dual antagonist action on the endocannabinoid and opioid systems.

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 48 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United States 2 4%
Unknown 46 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 23%
Researcher 9 19%
Student > Bachelor 5 10%
Other 4 8%
Professor 2 4%
Other 10 21%
Unknown 7 15%
Readers by discipline Count As %
Chemistry 9 19%
Agricultural and Biological Sciences 6 13%
Pharmacology, Toxicology and Pharmaceutical Science 5 10%
Medicine and Dentistry 4 8%
Biochemistry, Genetics and Molecular Biology 3 6%
Other 9 19%
Unknown 12 25%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 03 August 2014.
All research outputs
#19,944,091
of 25,373,627 outputs
Outputs from Drug Design, Development and Therapy
#1,310
of 2,268 outputs
Outputs of similar age
#235,267
of 322,707 outputs
Outputs of similar age from Drug Design, Development and Therapy
#12
of 23 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. This one is in the 18th percentile – i.e., 18% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,268 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.1. This one is in the 36th percentile – i.e., 36% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 322,707 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 24th percentile – i.e., 24% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 23 others from the same source and published within six weeks on either side of this one. This one is in the 34th percentile – i.e., 34% of its contemporaries scored the same or lower than it.